Losartan/hydrochlorothiazide
| Combination of | |
|---|---|
| Losartan | Angiotensin II receptor antagonist |
| Hydrochlorothiazide | Thiazide diuretic |
| Clinical data | |
| Trade names | Anzaplus, Cozaar comp, Hyzaar, Ocsaar Plus |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | C09DA01 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem (CID) | 24783652 |
| KEGG | D07895 |
Losartan/hydrochlorothiazide is a combination drug used as an antihypertensive, consisting of losartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic).
The losartan/hydrochlorothiazide combination preparation is marketed by Merck under the trade name Hyzaar and by Xeno Pharmaceuticals under the name Anzaplus. Merck, Sharp & Dohme market it as Ocsaar Plus in Israel. It is marketed as Cozaar comp in Sweden and South Africa.
In 2010, the patent for the combination expired, and a number of pharmaceutical companies promptly filed and received approval to sell the generic losartan, with and without hydrochlorothiazide, in the United States.[1]
Dosage
The recommended dosage of losartan-hydrochlorothiazide for adults with high blood pressure (hypertension) will vary between losartan-hydrochlorothiazide 50 mg/12.5 mg and losartan-hydrochlorothiazide 100 mg/25 mg once a day. Based on the initial blood pressure response and/or losartan-hydrochlorothiazide side effects, the dosage may be increased or decreased. With each change in dosage, it may take up to a month to see the full effect of losartan-hydrochlorothiazide on lowering blood pressure.
References
- ↑ https://web.archive.org/web/20100429175034/http://www.marketwatch.com/story/teva-announces-final-approval-of-generic-hyzaarr-and-cozaarr-2010-04-07. Archived from the original on April 29, 2010. Retrieved April 20, 2011. Missing or empty
|title=(help)